메뉴 건너뛰기




Volumn 25, Issue 7, 2011, Pages

Multiple myeloma precursor disease: Current clinical and epidemiological insights and future opportunities

Author keywords

[No Author keywords available]

Indexed keywords

BENIGN MONOCLONAL PROTEIN; CELL PROTEIN; MOLECULAR MARKER; UNCLASSIFIED DRUG;

EID: 79960212062     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note
Times cited : (10)

References (17)
  • 1
    • 72849156982 scopus 로고
    • Studies on conditions associated with disturbed gamma globulin formation (gammopathies)
    • Waldenstrom J. Studies on conditions associated with disturbed gamma globulin formation (gammopathies). Harvey Lect. 1960;56:211-31.
    • (1960) Harvey Lect , vol.56 , pp. 211-231
    • Waldenstrom, J.1
  • 2
    • 0017813724 scopus 로고
    • Monoclonal gammopathy of undetermined significance.Natural history in 241 cases
    • Kyle RA. Monoclonal gammopathy of undetermined significance. Natural history in 241 cases. Am J Med. 1978;64:814-26.
    • (1978) Am J Med , vol.64 , pp. 814-826
    • Kyle, R.A.1
  • 3
    • 77957964303 scopus 로고    scopus 로고
    • Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: Implications for recategorizing disease entities in the presence of evolving scientific evidence
    • Rajkumar SV, Kyle RA, Buadi FK. Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence. Mayo Clin Proc. 2010;85:945-8.
    • (2010) Mayo Clin Proc , vol.85 , pp. 945-948
    • Rajkumar, S.V.1    Kyle, R.A.2    Buadi, F.K.3
  • 4
    • 77957964303 scopus 로고    scopus 로고
    • Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: Implications for recategorizing disease entities in the presence of evolving scientific evidence
    • Rajkumar SV, Kyle RA, Buadi FK. Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence. Mayo Clin Proc. 2010;85:945-8.
    • (2010) Mayo Clin Proc , vol.85 , pp. 945-948
    • Rajkumar, S.V.1    Kyle, R.A.2    Buadi, F.K.3
  • 5
    • 0018848543 scopus 로고
    • Smoldering multiple myeloma
    • Kyle RA, Greipp PR. Smoldering multiple myeloma. N Engl J Med. 1980;302:1347-9.
    • (1980) N Engl J Med , vol.302 , pp. 1347-1349
    • Kyle, R.A.1    Greipp, P.R.2
  • 6
    • 0023790140 scopus 로고
    • Prognosis of asymptomatic multiple myeloma
    • Alexanian R, Barlogie B, Dixon D. Prognosis of asymptomatic multiple myeloma. Arch Intern Med. 1988;148:1963-5.
    • (1988) Arch Intern Med , vol.148 , pp. 1963-1965
    • Alexanian, R.1    Barlogie, B.2    Dixon, D.3
  • 7
    • 0027397466 scopus 로고
    • Risk of disease progression in asymptomatic multiple myeloma
    • Dimopoulos MA, Moulopoulos A, Smith T, et al. Risk of disease progression in asymptomatic multiple myeloma. Am J Med. 1993;94:57-61.
    • (1993) Am J Med , vol.94 , pp. 57-61
    • Dimopoulos, M.A.1    Moulopoulos, A.2    Smith, T.3
  • 8
    • 0028235301 scopus 로고
    • Detection of peripheral blood plasma cells as a predictor of disease course in patients with smouldering multiple myeloma
    • Witzig TE, Kyle RA, OFallon WM, Greipp PR. Detection of peripheral blood plasma cells as a predictor of disease course in patients with smouldering multiple myeloma. Br J Haematol. 1994;87:266-72.
    • (1994) Br J Haematol , vol.87 , pp. 266-272
    • Witzig, T.E.1    Kyle, R.A.2    Ofallon, W.M.3    Greipp, P.R.4
  • 9
    • 0038509089 scopus 로고    scopus 로고
    • Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders
    • a report of the International Myeloma Working Group
    • Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749-57.
    • (2003) Br J Haematol , vol.121 , pp. 749-757
  • 10
    • 77954610729 scopus 로고    scopus 로고
    • Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
    • Kyle RA, Durie BG, Rajkumar SV, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010;24:1121-7.
    • (2010) Leukemia , vol.24 , pp. 1121-1127
    • Kyle, R.A.1    Durie, B.G.2    Rajkumar, S.V.3
  • 11
    • 34250694807 scopus 로고    scopus 로고
    • Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma
    • Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007;356:2582-90.
    • (2007) N Engl J Med , vol.356 , pp. 2582-2590
    • Kyle, R.A.1    Remstein, E.D.2    Therneau, T.M.3
  • 12
    • 23044481861 scopus 로고    scopus 로고
    • Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance
    • Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 2005;106:812-7.
    • (2005) Blood , vol.106 , pp. 812-817
    • Rajkumar, S.V.1    Kyle, R.A.2    Therneau, T.M.3
  • 13
    • 38349136782 scopus 로고    scopus 로고
    • Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma
    • Dispenzieri A, Kyle RA, Katzmann JA, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood. 2008;111:785-9.
    • (2008) Blood , vol.111 , pp. 785-789
    • Dispenzieri, A.1    Kyle, R.A.2    Katzmann, J.A.3
  • 14
    • 34948907366 scopus 로고    scopus 로고
    • New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells
    • Perez-Persona E, Vidriales MB, Mateo G, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood. 2007;110:2586-92.
    • (2007) Blood , vol.110 , pp. 2586-2592
    • Perez-Persona, E.1    Vidriales, M.B.2    Mateo, G.3
  • 15
    • 78649726232 scopus 로고    scopus 로고
    • Multiple myeloma precursor disease
    • Landgren O, Waxman AJ. Multiple myeloma precursor disease. JAMA. 2010;304:2397-404.
    • (2010) JAMA , vol.304 , pp. 2397-2404
    • Landgren, O.1    Waxman, A.J.2
  • 17
    • 77957046247 scopus 로고    scopus 로고
    • Smoldering (asymptomatic) multiple myeloma: Revisiting the clinical dilemma and looking into the future
    • Waxman AJ, Kuehl WM, Balakumaran A, et al. Smoldering (asymptomatic) multiple myeloma: revisiting the clinical dilemma and looking into the future. Clin Lymphoma, Myeloma Leuk. 2010;10:248-57.
    • (2010) Clin Lymphoma, Myeloma Leuk , vol.10 , pp. 248-257
    • Waxman, A.J.1    Kuehl, W.M.2    Balakumaran, A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.